MRM Health Secures €55M Series B for Microbiome Therapeutics
MRM Health Secures €55 Million Series B Financing to Accelerate Development of Best-in-Class Microbiome-Based Biotherapeutics MRM Health NV, a pioneering clinical-stage biopharmaceutical company developing transformative microbiome-based therapeutics, announced the successful…
MEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for…
Texas Expands Access to Relief with House Bill 46 and an Enhanced Medical Cannabis Program
Texas Expands Medical Cannabis Access with House Bill 46: A New Era for Patient For thousands of Texans who live each day with the burden of chronic pain, traumatic brain…
Purdue Pharma Expands Low-Cost OUD Treatment to Prisons
Purdue Pharma Expands Access to Low-Cost Opioid Use Disorder Treatment in U.S. Correctional Facilities On the occasion of International Overdose Awareness Day, Purdue Pharma L.P. (“Purdue”) announced an expansion of…
Neurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors
Neurotech Pharmaceuticals Strengthens Leadership with Appointment of Dr. Peter J. McDonnell to Board of Directors Neurotech Pharmaceuticals, Inc., a privately held biotechnology company pioneering transformative therapies for chronic eye diseases,…
Enlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers
Enlaza Therapeutics and Vertex Pharmaceuticals Forge Multi-Billion-Dollar Collaboration to Advance Next-Generation Covalent Biologics in Autoimmune Diseases and Conditioning Therapies Enlaza Therapeutics (“Enlaza” or the “Company”), a pioneering biotechnology firm and…
CapVest Set to Acquire Majority Ownership in STADA from Bain Capital and Cinven
CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven CapVest Partners LLP (“CapVest”), a global investment firm with a reputation for building essential businesses across healthcare, consumer,…
Daiichi Sankyo Begins Development of Oral Triple Combo Lipid-Lowering Tablets for LDL-C Management
Daiichi Sankyo Advances Cardiovascular Care with Development of Oral Triple Combination Lipid-Lowering Tablets A New Chapter in Cholesterol Management Daiichi Sankyo Europe has unveiled an ambitious new initiative: the development…
Alnylam Moves Zilebesiran into Global Phase 3 Trial
Alnylam Advances Zilebesiran Into Global Phase 3 Cardiovascular Outcomes Trial Following Promising Phase 2 KARDIA Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized leader in RNA interference (RNAi) therapeutics, announced…
Bristol Myers Squibb Showcases Global Real-World Data on Camzyos at ESC 2025
Bristol Myers Squibb Showcases Landmark Real-World Data on Camzyos in Obstructive Hypertrophic Cardiomyopathy at ESC Congress 2025 Bristol Myers Squibb (NYSE: BMY) unveiled new results from its global COLLIGO-HCM study…
BeOne Reports Positive Results for Sonrotoclax in MCL
BeOne Medicines Announces Positive Topline Results from Phase 1/2 Study of Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…
TechImmune Names James F. Young, Ph.D. as Executive Chairman
James F. Young, Ph.D. Appointed Executive Chairman of TechImmune, Bringing Four Decades of Vaccine Innovation and Leadership to the Fight Against Long COVID TechImmune, a biotechnology company at the forefront…